In this episode of the Psychedelic Spotlight podcast we speak with Richard Skaife who is the Co-Founding Partner of The Conscious Fund.
Similar Posts
The Revolution in Mental Health Care: Psychedelics | PSILERA
In today’s episode, we speak with the leaders of Psilera…
The Awakening of Consciousness Conference with Paul Karasik
In this episode, Matthew and Paul discuss The Psychedelic Institute’s aspirations with the launch of the Awakening of Consciousness Conference, the differences between legalization and decriminalization, and the importance of being brave, and thinking outside the box in understanding what it takes to make the most of one’s own experience of sacred plant medicines.
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
0:32 – Norway Decriminalization Bill
1:59 – Psychedelic Market Stats
3:21 – Magic Mushrooms to Treat Obesity
5:40 – Ketamine to Treat Suicidal Thoughts?
7:09 -The Acid King?
8:58 – MindMed (MMED/MMEDF/MMQ) Updates
10:04 – Compass Pathways (CMPS) Updates
11:44 – Atai Life Sciences Updates
14:02 – Numinus (NUMI) Updates
15:13 – CYBIN Updates
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
Will MAPS IPO? The FIRST American Psychedelic ETF (PSY), New LSD Studies & More
There were LOTS of general news important for the psychedelic industry as a whole and very important study results that will influence some of our favorite stocks such as MindMed (MMED / MNMD / MMQ) and Compass Pathways (CMPS)!
In today’s episode we’ll cover a new American psychedelic ETF which is hitting the market under ticker symbol PSY, some new psilocybin and LSD studies, whether MAPS will turn into a public company and some updates on the California and New York bills we have been covering for a while now.
Enjoy the episode!
Timestamps:
0:00 – Intro
0:40 – The First American Psychedelic ETF (PSY)
5:50 – MAPS Considering An IPO?
12:28 – Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical SSRIs
15:29 – New Study On How LSD Affects The Brain
21:08 – The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD
23:00 – New York Bill Proposes State-Sponsored Psychedelic Research Institute
Links:
New Psychedelic ETF (NYSE : PSY) :
https://www.defianceetfs.com/psy/
https://psychedelicspotlight.com/psy-first-u-s-psychedelic-etf/
Maps Considering An IPO?:
https://www.reddit.com/r/shroomstocks/comments/nqoy0z/maps_considering_ipo/
https://youtu.be/v2HycPpjf6Y
Study Shows Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical Antidepressants:
https://thedalesreport.com/psychedelics/study-shows-psilocybin-assisted-therapy-4-times-more-effective-than-typical-antidepressants/
New Study On How LSD Affects The Brain:
https://www.theguardian.com/science/2021/may/19/acid-test-scientists-show-how-lsd-opens-doors-of-perception
The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD:
https://www.marijuanamoment.net/california-senate-approves-bill-to-legalize-possession-of-psychedelics-like-psilocybin-and-lsd/
New York Bill Proposes State-Sponsored Psychedelic Research Institute:
https://psychedelicspotlight.com/new-york-bill-psychedelic-research-institute/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #MAPS
MindMed Joins the NASDAQ : MindMed Stock Analysis & Prediction (MMED / MMEDF)
MindMed has officially been added to the NASDAQ Global Market.
On April 22nd, MindMed filed an 8-A12B with the SEC which ultimately allowed it to uplist to the NASDAQ. For NEO owners, the ticker symbol will remain MMED, for OTC owners, it’ll change to MNMD.
On 23rd of April, MindMed announced that as onf April 27th MindMed will be trading as MNMD on the NASDAQ. This means that MindMed was able to meet financial and listing requirements. Typically when securities get listed on major stock exchanges, they are highly traded and prices higher than those that trade OTC. Being able to uplist and trade on an exchange such as the NASDAQ will provide MindMed exposure and visibility to a larger market which might, in the short term, 2, 3 or 4x MindMed’s stock price as more people buy the stock due to FOMO. This happened when Compass Pathways IPOed which almost 4xed its share price within a few days from $17 to $60 before CMPS dropped back down to $33.
Where does MindMed go from here on? MMEDF is just at the beginning of their long-term growth trajectory. Some investors might feel inclined to take profits, which is absolutely understandable. However, like I’ve been saying in the majority of my MindMed episodes or any psychedelic stock videos, the potential returns could be a lot higher in a few years, when/if MindMed shows proof that their medicines work and gets FDA approval.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNasdaq #MindMedstock
MindMed Taking On The $30 BILLION Pain Relief Industry? [MMED / MNMD Expanding with Project Angie ]
Project Angie: Can MindMed Disrupt the Pain Relief Industry? [MMED / MNMD Expanding Horizons]
Breaking NEWS: MindMed ( MNMD / MMED / MMQ ) launching a new flagship program called Angie to advance the development of psychedelics, including LSD and potentially penetrate the pain killer industry by treating pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain:
MindMed will initiate a study of LSD in a severe pain indication. MMED is currently preparing a pre-IND briefing package for this Phase 2a Proof of Concept study. They plan to submit to the FDA in the second half of 2021.
( As a note, that means they could present this doc anywhere between July 1st and December 31st. So it is conceivable that this trial could start at the tail end of 2021, if this doc gets presented at the beginning of that period.)
The second indication that MindMed is evaluating is “the common, often debilitating, chronic pain syndrome”.
Link to the 1964 study testing the LSDs ability to treat pain in cancer patients, and it had dual surprising results
: file:///C:/Users/maria/Downloads/Study_of_Lysergic_Acid_Diethylamide_as_an.13.pdf
Link to the 2020 a study was published that had among its authors 2 prominent MindMed collaborators: Mattias Liechti and Kim Kuypers: https://journals.sagepub.com/doi/full…
Link to the 2017study: https://www.ncbi.nlm.nih.gov/pmc/arti…
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MindMed ‘ s Press Release on Project Angie : https://mindmed.co/news/press-release…
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD